Literature DB >> 24425867

Oxicams bind in a novel mode to the cyclooxygenase active site via a two-water-mediated H-bonding Network.

Shu Xu1, Daniel J Hermanson, Surajit Banerjee, Kebreab Ghebreselasie, Gina M Clayton, R Michael Garavito, Lawrence J Marnett.   

Abstract

Oxicams are widely used nonsteroidal anti-inflammatory drugs (NSAIDs), but little is known about the molecular basis of the interaction with their target enzymes, the cyclooxygenases (COX). Isoxicam is a nonselective inhibitor of COX-1 and COX-2 whereas meloxicam displays some selectivity for COX-2. Here we report crystal complexes of COX-2 with isoxicam and meloxicam at 2.0 and 2.45 angstroms, respectively, and a crystal complex of COX-1 with meloxicam at 2.4 angstroms. These structures reveal that the oxicams bind to the active site of COX-2 using a binding pose not seen with other NSAIDs through two highly coordinated water molecules. The 4-hydroxyl group on the thiazine ring partners with Ser-530 via hydrogen bonding, and the heteroatom of the carboxamide ring of the oxicam scaffold interacts with Tyr-385 and Ser-530 through a highly coordinated water molecule. The nitrogen atom of the thiazine and the oxygen atom of the carboxamide bind to Arg-120 and Tyr-355 via another highly ordered water molecule. The rotation of Leu-531 in the structure opens a novel binding pocket, which is not utilized for the binding of other NSAIDs. In addition, a detailed study of meloxicam·COX-2 interactions revealed that mutation of Val-434 to Ile significantly reduces inhibition by meloxicam due to subtle changes around Phe-518, giving rise to the preferential inhibition of COX-2 over COX-1.

Entities:  

Keywords:  Cyclooxygenase (COX) Pathway; Drug Action; Enzyme Structure; Protein Drug Interactions; X-ray Crystallography

Mesh:

Substances:

Year:  2014        PMID: 24425867      PMCID: PMC3945341          DOI: 10.1074/jbc.M113.517987

Source DB:  PubMed          Journal:  J Biol Chem        ISSN: 0021-9258            Impact factor:   5.157


  41 in total

1.  Structural analysis of NSAID binding by prostaglandin H2 synthase: time-dependent and time-independent inhibitors elicit identical enzyme conformations.

Authors:  B S Selinsky; K Gupta; C T Sharkey; P J Loll
Journal:  Biochemistry       Date:  2001-05-01       Impact factor: 3.162

2.  PRODRG: a tool for high-throughput crystallography of protein-ligand complexes.

Authors:  Alexander W Schüttelkopf; Daan M F van Aalten
Journal:  Acta Crystallogr D Biol Crystallogr       Date:  2004-07-21

3.  Flexibility of the NSAID binding site in the structure of human cyclooxygenase-2.

Authors:  C Luong; A Miller; J Barnett; J Chow; C Ramesha; M F Browner
Journal:  Nat Struct Biol       Date:  1996-11

4.  Structural basis for selective inhibition of cyclooxygenase-2 by anti-inflammatory agents.

Authors:  R G Kurumbail; A M Stevens; J K Gierse; J J McDonald; R A Stegeman; J Y Pak; D Gildehaus; J M Miyashiro; T D Penning; K Seibert; P C Isakson; W C Stallings
Journal:  Nature       Date:  1996 Dec 19-26       Impact factor: 49.962

5.  Investigating substrate promiscuity in cyclooxygenase-2: the role of Arg-120 and residues lining the hydrophobic groove.

Authors:  Alex J Vecchio; Benjamin J Orlando; Ritwik Nandagiri; Michael G Malkowski
Journal:  J Biol Chem       Date:  2012-05-25       Impact factor: 5.157

6.  Human cyclooxygenase-2 is a sequence homodimer that functions as a conformational heterodimer.

Authors:  Liang Dong; Alex J Vecchio; Narayan P Sharma; Brice J Jurban; Michael G Malkowski; William L Smith
Journal:  J Biol Chem       Date:  2011-04-05       Impact factor: 5.157

7.  Features and development of Coot.

Authors:  P Emsley; B Lohkamp; W G Scott; K Cowtan
Journal:  Acta Crystallogr D Biol Crystallogr       Date:  2010-03-24

8.  Analogues and derivatives of tenoxicam. 1. Synthesis and antiinflammatory activity of analogues with different residues on the ring nitrogen and the amide nitrogen.

Authors:  D Binder; O Hromatka; F Geissler; K Schmied; C R Noe; K Burri; R Pfister; K Strub; P Zeller
Journal:  J Med Chem       Date:  1987-04       Impact factor: 7.446

9.  A novel mechanism of cyclooxygenase-2 inhibition involving interactions with Ser-530 and Tyr-385.

Authors:  Scott W Rowlinson; James R Kiefer; Jeffery J Prusakiewicz; Jennifer L Pawlitz; Kevin R Kozak; Amit S Kalgutkar; William C Stallings; Ravi G Kurumbail; Lawrence J Marnett
Journal:  J Biol Chem       Date:  2003-08-18       Impact factor: 5.157

10.  Iterative model building, structure refinement and density modification with the PHENIX AutoBuild wizard.

Authors:  Thomas C Terwilliger; Ralf W Grosse-Kunstleve; Pavel V Afonine; Nigel W Moriarty; Peter H Zwart; Li Wei Hung; Randy J Read; Paul D Adams
Journal:  Acta Crystallogr D Biol Crystallogr       Date:  2007-12-05
View more
  30 in total

1.  Structural basis for selective inhibition of Cyclooxygenase-1 (COX-1) by diarylisoxazoles mofezolac and 3-(5-chlorofuran-2-yl)-5-methyl-4-phenylisoxazole (P6).

Authors:  Gino Cingolani; Andrea Panella; Maria Grazia Perrone; Paola Vitale; Giuseppe Di Mauro; Cosimo G Fortuna; Roger S Armen; Savina Ferorelli; William L Smith; Antonio Scilimati
Journal:  Eur J Med Chem       Date:  2017-06-24       Impact factor: 6.514

2.  13-Methylarachidonic acid is a positive allosteric modulator of endocannabinoid oxygenation by cyclooxygenase.

Authors:  Shalley N Kudalkar; Spyros P Nikas; Philip J Kingsley; Shu Xu; James J Galligan; Carol A Rouzer; Surajit Banerjee; Lipin Ji; Marsha R Eno; Alexandros Makriyannis; Lawrence J Marnett
Journal:  J Biol Chem       Date:  2015-02-02       Impact factor: 5.157

3.  Action at a distance: mutations of peripheral residues transform rapid reversible inhibitors to slow, tight binders of cyclooxygenase-2.

Authors:  Anna L Blobaum; Shu Xu; Scott W Rowlinson; Kelsey C Duggan; Surajit Banerjee; Shalley N Kudalkar; William R Birmingham; Kebreab Ghebreselasie; Lawrence J Marnett
Journal:  J Biol Chem       Date:  2015-03-30       Impact factor: 5.157

Review 4.  The Role of Exparel Plus Meloxicam for Postoperative Pain Management.

Authors:  Alan David Kaye; Matthew B Novitch; Sam F Carlson; Mitchell C Fuller; Shane W White; Alexander R Haroldson; Jennifer A Kaiser; Mohamed A Elkersh; Andrew J Brunk; George M Jeha; Elyse M Cornett
Journal:  Curr Pain Headache Rep       Date:  2020-01-30

5.  D3R Grand Challenge 4: prospective pose prediction of BACE1 ligands with AutoDock-GPU.

Authors:  Diogo Santos-Martins; Jerome Eberhardt; Giulia Bianco; Leonardo Solis-Vasquez; Francesca Alessandra Ambrosio; Andreas Koch; Stefano Forli
Journal:  J Comput Aided Mol Des       Date:  2019-11-06       Impact factor: 3.686

6.  Dual cyclooxygenase-fatty acid amide hydrolase inhibitor exploits novel binding interactions in the cyclooxygenase active site.

Authors:  Michael C Goodman; Shu Xu; Carol A Rouzer; Surajit Banerjee; Kebreab Ghebreselasie; Marco Migliore; Daniele Piomelli; Lawrence J Marnett
Journal:  J Biol Chem       Date:  2018-01-11       Impact factor: 5.157

7.  Crystal Structure of Aspirin-Acetylated Human Cyclooxygenase-2: Insight into the Formation of Products with Reversed Stereochemistry.

Authors:  Michael J Lucido; Benjamin J Orlando; Alex J Vecchio; Michael G Malkowski
Journal:  Biochemistry       Date:  2016-02-19       Impact factor: 3.162

8.  Fluorescent indomethacin-dansyl conjugates utilize the membrane-binding domain of cyclooxygenase-2 to block the opening to the active site.

Authors:  Shu Xu; Md Jashim Uddin; Surajit Banerjee; Kelsey Duggan; Joel Musee; James R Kiefer; Kebreab Ghebreselasie; Carol A Rouzer; Lawrence J Marnett
Journal:  J Biol Chem       Date:  2019-04-18       Impact factor: 5.157

Review 9.  Oxicams, a class of nonsteroidal anti-inflammatory drugs and beyond.

Authors:  Shu Xu; Carol A Rouzer; Lawrence J Marnett
Journal:  IUBMB Life       Date:  2014-12-23       Impact factor: 3.885

10.  Binding of indomethacin methyl ester to cyclooxygenase-2. A computational study.

Authors:  Menyhárt-Botond Sárosi
Journal:  J Mol Model       Date:  2018-06-05       Impact factor: 1.810

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.